Edwards Lifesciences provides The Vigilance II monitor, which is designed to gives users the ability to present complex hemodynamic data in a simplified way to paint a clearer picture of the patient’s hemodynamic status.
Features include:
* Continuous CO, SvO2, EDV, SVR and other measured and derived parameters are presented on customized displays selected by the clinician.
* Onscreen, customized trend, data relationship and stat displays provide a complete picture of blood flow and tissue oxygenation for precision patient management.

March 4, 2008 - Visage Imaging will unveil its Visage Thin Client solutions portfolio, and demonstrate scalability for integrated 2D, 3D and 4D advanced visualization and other new tools for cardiology, radiology and other subspecialties, at the European Congress of Radiology (ECR) in Vienna, Austria, March 7-10.

March 4, 2008 - By using a dual-source technique on a single computed tomography (CT) system, a research team at the Medical University of South Carolina’s (MUSC) Heart & Vascular Center was able to make a comprehensive diagnosis of heart disease, according to a report published in the current issue Circulation.

The new version of Visage CS Cardiac Analysis is said to feature a set of new tools and optimizations such as calcium scoring, enhanced reporting and manual editing of the left ventricle geometry. Visage CS Cardiac Analysis is designed to allow viewing and post-processing of even the largest multi-phase cardiac CT studies, using Visage’s server-based thin-client performance.

March 3, 2008 - The FDA, National Heart Lung & Blood Institute and National Science Foundation are hosting a Workshop on Computer Methods for Cardiovascular Devices, in Bethesda, MD, from March 18-19 to address regulatory and technical issues with medical devices.

March 3, 2008 - CardiacQA surpassed 20,000 reports on its Nuclear Report Generator, marking a milestone for the web-based provider of quality assurance tools and nuclear reporting solutions for cardiology practices before its 2008 release of its Echocardiography Report Generator.
CardiacQA clients are able to take advantage of CardiacQA solutions, over the Internet, designed to reduce the time and costs traditionally associated with similar local installations. CardiacQA currently supports customers of all sizes, with a focus in the outpatient cardiology market.

March 3, 2008 - Vermillion Inc. has entered into an exclusive license agreement with Stanford University to develop and commercialize a novel biomarker panel used to assess the risk of peripheral artery disease (PAD), as both groups aim to develop tools to expedite treatment and enhance patient outcomes.
Under the terms of the agreement, Vermillion is granted exclusive rights to the biomarker panel, and will undertake the development and commercialization of a PAD blood test, which utilizes the multi-marker panel to stratify an individual’s risk for developing the disease.

March 3, 2008 – The FDA granted 510(k) clearance for the AIGISRX CRMD Anti-Bacterial Envelope by Tyrxpharma, a cardiac rhythm medical device intended to immobilize and reduce bacterial infection of a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body.

March 3, 2008 – Covidien said that it has tentative FDA clearance for its Abbreviated New Drug Application (ANDA) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection, a generic of Cardiolite1, which is a myocardial perfusion imaging agent used for detecting coronary artery disease.

The branded product is utilized in nearly 60 percent of the 15 million myocardial perfusion imaging studies performed in the U.S. annually.

February 29, 2008 - Physicians began performing the first European implants of the COGNIS cardiac resynchronization therapy defibrillator (CRT-D) and the TELIGEN implantable cardioverter defibrillator (ICD) by Boston Scientific Corp. after both devices received CE Mark last month.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now